EGR1 mediates MDR1 transcriptional activity regulating gemcitabine resistance in pancreatic cancer

Zhe Yang,Feiran Chen,Dafu Wei,Fengping Chen,Haixing Jiang,Shanyu Qin
DOI: https://doi.org/10.1186/s12885-024-12005-2
IF: 4.638
2024-02-27
BMC Cancer
Abstract:Gemcitabine is a cornerstone drug for the treatment of all stages of pancreatic cancer and can prolong the survival of patients with pancreatic cancer, but resistance to gemcitabine in pancreatic cancer patients hinders its efficacy. The overexpression of Early growth response 1(EGR1) in pancreatic ductal adenocarcinoma as a mechanism of gemcitabine chemoresistance in pancreatic cancer has not been explored. The major mechanisms of gemcitabine chemoresistance are related to drug uptake, metabolism, and action. One of the common causes of tumor multidrug resistance (MDR) to chemotherapy in cancer cells is that transporter proteins increase intracellular drug efflux and decrease drug concentrations by inducing anti-apoptotic mechanisms. It has been reported that gemcitabine binds to MDR1 with high affinity. The purpose of this research was to investigate the potential mechanisms by which EGR1 associates with MDR1 to regulate gemcitabine resistance in pancreatic cancer cells.
oncology
What problem does this paper attempt to address?